Novel Antiangiogenic Peptides for Treatment of Exudative AMD

Project: Research project

Description

Pathological ocular angiogenesis is a key component of several diseases that
cause irreversible blindness. VEGF-neutralizing antibodies given as intravitreal injections at
approximately 6 week intervals are standard of care in the treatment of exudative (wet) agerelated
macular degeneration, showing that anti-angiogenic agents can slow progress of AMD,
the foremost cause of blindness in the industrialized world. Injections this frequent are painful
and damaging to the eye, and VEGF expression increases to resist therapy. The objective of
this proposal is to discover novel anti-angiogenic agents whose mechanism is to replace the
activities of natural inhibitors (TSP and PEDF) of angiogenesis which are insufficiently
expressed in diseased eyes. The proposed anti-angiogenic agent is based on small synthetic
peptides which potently mimic the activity of these natural inhibitor proteins. TSP- and PEDFmimetic
peptides were discovered at Abbott Laboratories and Northwestern University. Unlike
antibodies, these small peptides can be attached to polymers via specific chemistry to affect
their slow intraocular release after intravitreal injection, with the aim of greatly reducing the
frequency of treatment injections. New versions of the peptides will be needed for polymer
conjugation. The goal at the end of year 5 is to file an IND for clinical trial of a new entity for
treatment of wet AMD to slow the onset of blindness with less frequent intravitreal injection.
StatusFinished
Effective start/end date3/1/142/28/15

Funding

  • University of Wisconsin-Madison (553K221 // 5R24EY022883-02)
  • Kennedy Institute - National Eye Clinic (553K221 // 5R24EY022883-02)

Fingerprint

Intravitreal Injections
Blindness
Peptides
Vascular Endothelial Growth Factor A
Pathologic Neovascularization
Injections
Eye Diseases
Standard of Care
Neutralizing Antibodies
Polymers
Therapeutics
Clinical Trials
Proteins